All Licensing Opportunities

We have colour coded the opportunities by product type to make it easier to pick out the opportunities that you are interested in.  Material sales (e.g. hybridomas and other cell lines) are listed under the materials sales section of the website.

  • 26046 Acetylation of cytokeratin 8

    Dr Bernard Corfe at Sheffield University has discovered that acetylation patterns of cytokeratins, in particular cytokeratin 8, can be correlated with cancer or a predisposition to cancer.

    View more

    The cytoskeleton is a scaffold upon which the cellular architecture is based. The eukaryotic cytoskeleton comprises actin filaments, microtubules and intermediate filaments. Intermediate filaments include the cytokeratins. While their primary role is mechanical support, it is becoming increasingly apparent that the cytokeratins are also mediators of the subcellular distribution of other proteins and that they also have a role in cell signalling pathways. Regulation of cytokeratin expression activity occurs, at least in part, through changes in post translational modification.

    The discovery that acetylation patterns of cytokeratins, in particular cytokeratin 8, can be correlated with cancer or a predisposition to cancer, therefore raising the prospect of novel diagnostic tests and therapies. This work is the subject of a filed patent application.

    For more information please download a summary of the technology from the link below

    LicensingOpportunity26046Acetylationofcytokeratin8.pdf

  • 27044 Fluorcanasite glass ceramic for dentistry

    Researchers at the University of Sheffield have developed a novel, fully-synthetic fluorcanasite material with class-leading properties that is inexpensive to produce

    View more

    The dental market is well positioned to expand quickly over the next 30 years with 2 key underlying trends set to drive growth:

    • an ageing and relatively wealthy population in the advanced economies

    • rapid growth of a new middle-class in the emerging economies that will yield at least one billion new dental patients

    Within the dental market sector, indirect dental restorations are a large and growing market, with over 20 million dental restorations carried out in the US per year and in the UK in 1998, over 55% of dentate adults had at least one decayed or unsound tooth.

    Researchers at the University of Sheffield have developed a novel, fully-synthetic fluorcanasite material with class-leading properties and that is inexpensive to produce. Our material, Fluorcanasite S82, is stronger than currently available materials, has higher fracture toughness, has class leading aesthetic properties and is designed to be machinable with all common CAD/CAM systems. Fluorcanasite is strikingly more similar in appearance to a real tooth than competitor products.

    We are currently undertaking work to ensure regulatory compliance for the material and are making rapid progress towards compiling a data file suitable for applying for CE marking/FDA approval.

     

    For further information please download the summary document below:

    Outlicensingopportunity27044Fluorcanasiteglassceramicfordentistry.pdf

  • 27041 Catalytic methods for preparation of chiral amines

    Researchers at the University of Sheffield have developed and optimised new systems for the preparation of chiral amines in almost quantitative yield and as, essentially, one stereoisomer. 

    View more

    The worldwide pharmaceutical and fine chemical industry has an increasing need for more efficient and selective methods for the construction of molecules of high commercial value. However, many organic, biochemical and biological compounds are chiral (that is they have a structure that cannot be superimposed on its mirror image) which, when used as pharmaceuticals, can differ markedly in their efficacy or toxicity. Additionally, strict regulatory procedures introduced after previous problems with pharmaceutical stereo isomers) now dictate that any chiral compounds (existing as two enantiomeric molecules) must be evaluated in both of these forms. This has led to an enormous global interest in developing new methods and techniques for the production of chiral molecules. Controlling the chirality of the final product using current methods is complicated and involves a great deal of optimisation of many different factors which affect the outcome of the catalytic process, such as the catalyst structure, catalyst loading, solvent, temperature and time. Relatively minor changes in any one of these factors can have a significant and often detrimental effect on the stereo chemical outcome of the reaction.

    Researchers at the University of Sheffield have developed and optimised new systems for the preparation of chiral amines in almost quantitative yield and as, essentially, one stereoisomer. Their system is also unique since it allows a ‘one-pot’ two-step transformation, operating efficiently with only 1% of catalyst compared to those reported in the literature, which require 10%. These catalysts also have the advantage of being easily prepared and do not require transition metals, which can be expensive and can contaminate the end product.

    For more information please download a summary of the technology from the link below

    Outlicensingopportunity27041Catalyticmethodsforpreparationofchiralamines.pdf

  • 29023 Therapeutics for prion diseases

    A research group at the University of Sheffield have discovered a novel class of compounds in cellular assays for anti-prion activity.  The best known property of cellular prion protein (PrPC) is its unique ability to undergo conformational change into a pathogenic conformer, PrPSc, that accumulates in the brain as insoluble aggregates. This process leads to neuronal dysfunction and progressive neurodegeneration, a distinctive feature shared by all transmissible spongiform encephalopathies (TSE), a family of lethal neurodenenerative diseases including scrapie in sheep, “mad cow disease” (BSE) in cattle, Kuru and Creutzfeldt-Jakob disease in humans. There is currently no effective treatment.

    View more

    Prion diseases, or transmissible spongiform encephalopathies (TSEs), are invariably fatal neurodegenerative disorders affecting humans and animals. As yet, no effective curative or prophylactic therapy exists. 

    Cellular prion protein, PrPC, is a membrane-anchored, neuronal glycoprotein. Its primary sequence consists of a linear peptide chain of approximately 210 amino acids encoded by the human PRNP gene, located on chromosome 20. The protein is synthesised in the endoplasmic reticulum, transits the Golgi, then is delivered to the outer membrane as a peripheral membrane protein covalently attached to lipid rafts (via GPI anchor) where it participates in its normal function(s). PrPC is expressed in many cell types, especially neuronal cells, and its architecture is well reserved across vertebrates, although a clearly defined role in evolution and normal physiological function remain elusive. In the past two decades, an impressive number of studies have investigated nearly every aspect of prion function.

    The best known property of PrPC is its unique ability to undergo conformational change into a pathogenic conformer, PrPSc, that accumulates in the brain as insoluble aggregates. This process leads to neuronal dysfunction and progressive neurodegeneration, a distinctive feature shared by all transmissible spongiform encephalopathies (TSE), a family of lethal neurodenenerative diseases including scrapie in sheep, “mad cow disease” (BSE) in cattle, Kuru and Creutzfeldt-Jakob disease in humans. There is currently no effective treatment.

    A research group at the University of Sheffield has been engaged in discovering lead compounds against prion proteins. We have now filed a patent application on a novel class of indole-3-glyoxylamide compounds with potent antiprion activities in cellular assay. This class of compounds have good preliminary in vitro DMPK profiles in general.  For summary information please download the summary document below: 

    290231pagesummary.pdf

  • 26022 Tribbles

    Researchers at the University of Sheffield have recently identified a novel protein family, Tribbles (trb), as regulators of Mitogen Activated Protein Kinase (MAPK) pathways.  MAPKs are involved in the regulation of development, cell activation, proliferation and vascular contraction and are classified into at least three distinct groups (JNK, p38 and ERK kinases).  The academic team have shown that tribbles proteins modulate the activation of JNK, ERK and p38 MAPKs in a cell type and concentration specific manner.

    View more

    Researchers at the University of Sheffield have recently identified a novel protein family, Tribbles (trb), as regulators of Mitogen Activated Protein Kinase (MAPK) pathways.  MAPKs are involved in the regulation of development, cell activation, proliferation and vascular contraction and are classified into at least three distinct groups (JNK, p38 and ERK kinases).  The academic team have shown that tribbles proteins modulate the activation of JNK, ERK and p38 MAPKs in a cell type and concentration specific manner.

    The research has also shown that expression of one member of the Tribbles family, trb-1, has a strong anti-proliferative function in vascular smooth muscle cells which may be of physiological importance in the development and progression of atherosclerosis.  The observations reveal trb-1 to be a novel, central regulator of vascular smooth muscle cells function.  Furthermore, modulation of trb-1 has been shown to enhance the proliferation rate of human primary cells which is of use in several applications including tissue engineering, autologous skin grafts and industrial applications which require larger quantities of primary cells such as drug screening.       

    For more information please download a summary of the technology from the link below:

    Outlicensingopportunity26022Tribbles.pdf

  • 27024 Tribbles-2

    According to the World Health Organisation, cardiovascular diseases kill more people in Europe and North America than any other disease.  The formation of foam cells from macrophages and monocytes is a hallmark of the development of atherosclerotic lesions and plaques, which can lead to acute coronary syndrome (ACS).  The identification of a novel family of proteins, Tribbles, which regulate the upstream processes involved in causing plaque formation and atherosclerosis provides a potential target for therapeutic intervention and diagnostics. 

    View more

    The identification of a novel family of proteins, Tribbles, which regulate the upstream processes involved in causing plaque formation and atherosclerosis provides a potential target for therapeutic intervention and diagnostics.  There is a mounting body of evidence which suggests that dysregulation of Tribbles proteins can lead to cancerous transformation, type II diabetes and the development of metabolic syndromes. 

    One member of the tribbles family, trb-2, has been identified as novel regulator of Mitogen Activated Protein Kinase (MAPK) activation and is also a binding partner and negative regulator of selected Mitogen Activated Protein Kinase Kinases (MAPKKs).  University of Sheffield researchers have discovered that down-regulation of trb-2 is involved with the inflammatory activation of macrophages and that trb-2 is selectively down-regulated in patients with ACS.  They have also obtained evidence for the mechanism of the anti-inflammatory properties of statins.

    A patent application has been filed which includes the use of Trb-2 modulators as a therapeutic.The work outlined above shows that statins may be intimately involved in altering inflammatory monocyte physiology. The research group have evidence of the mechanism by which statins modulate the level of expression of central regulatory components of inflammatory signal processing. The data shows that trb-2 is down-regulated during inflammatory activation of monocytes.  We are currently seeking a commercial partner to explore the potential of trb-2 as a target for anti-inflammatory therapies.

    For more information please download a summary of the technology from the link below:

    LicensingOpportunity27024Tribbles2.pdf

  • 26048 TILRR

    The present invention relates to the finding that TILRR, a distinct regulator of TIR function, specifically impacts the NF-kB induced inflammatory response, thus making possible highly selective targeting. 

    View more

    The receptors recognize a range of distinct ligands and co-receptors, but activate responses through an evolutionary conserved homologous region, the TIR domain .  The importance of TILRR as a target (as opposed to other Toll like and IL-1 receptors) is because TILRR activates the TIR domain in a distinct manner and regulates inflammatory responses and other NF- kB induced events through separate portions of the core protein, making it possible to selectively control downstream events.  TILRR has a unique combination of characteristics, including selective/distinct regulation together with a cell surface location, making TILRR a readily accessible and highly specific regulator; very desirable attributes in drug design and development.

    We have developed the use of TILRR as a novel therapeutic agent. 

    For more information please download a summary of the technology from the link below.

    LicensingOpportunity26048TILRR.pdf

  • 27010 Remote Blood Glucose Monitor

    A team of engineers and clinicians from the University of Sheffield, Sheffield Children’s Hospital and Sheffield Teaching Hospitals have developed an electronic system to provide automated collection, delivery, analysis and feedback of a patient’s blood glucose measurement via wireless technology for remote medical monitoring and feedback by a clinician. 

    View more

    The compact monitor is a compatible “add on” to existing glucose meters and communicates wirelessly with the patient’s mobile phone.  The phone then sends text messages to a server automatically; bespoke software then stores these readings in a database in order to present, analyse and prioritise the data to the clinician to provide feedback to the patient as appropriate.  The system offers several advantages over current practice as it is does not require expensive hardware and is compatible with any wireless-enabled mobile phone, making use of existing ICT infrastructure.

    The system may be particularly useful in both juvenile and elderly diabetics who often have difficulty in managing their blood glucose.  Type I diabetics follow a strict daily regime for management of blood glucose levels, a process facilitated by several blood glucose tests each day.  In 2003, there were a total of 517 million diabetics in France, Germany, Italy, Japan, Spain, UK and the USA (World Health Organisation, WHO).  Around 10% of this population had Type 1 diabetes.   It is estimated that diabetes related complications cost the NHS around £1.2 billion annually. In the US, the healthcare costs for a person with diabetes are estimated at over $13,000 per year. Current opinion is that better management of blood glucose levels can lead to a 40% cost reduction in diabetes related complications.  In North America alone, $98 billion is spent per year on the care and impact of diabetes. 

    The Sheffield technology will help improve quality of life for patients as well as reducing the cost of diabetes to healthcare providers.   

     

    For further information please download a summary of the technology from the link below.

    LicensingOpportunity27010RemoteBloodGlucoseMonitor.pdf

  • 27012 FPGA system for protein identification

    This system reduces the time required to identify a protein from mass spectrometry data from tens of minutes to less than 100 milliseconds

    View more

    This is achieved by running bioinformatics algorithms on highly optimised digital processors that are programmed to run on a 'reconfigurable chip', the FPGA (Field Programmable Gate Array). An FPGA is a type of digital integrated circuit that can be reprogrammed after it is manufactured. The FPGA devices sit on a reconfigurable card that is interfaced with a PC via the standard PCI bus. The card can be configured to have 4 FPGA devices and 3Gbytes of RAM memory to store entire protein databases.  The processing speed of this system allows the user to get a match to a database entry in real-time.

    For further information please download a summary of the technology from the link below.

    LicensingOpportunity27012FPGAsystemforrealtimeproteinidentification.pdf

  • 25010 Speech Therapy Software

    Academics at Sheffield (Prof. Rosemary Varley and Dr Sandra Whiteside) have developed clinical evidence-based software that has been shown to treat apraxia and aphasia in clinical trials. 

    View more

    This software has now been exclusively licensed. 

  • 27032 Auditory Neuronal Differentiation

    A patent application has been filed relating to an agent for treating sensorineural hearing loss

    View more

    Researchers at Sheffield University have found that extracellular proteases can induce neural differentiation from human auditory stem cells in vitro, including the growth of extensive neurites.  The potential exists that this or other specific proteases or receptor agonists could be used to induce auditory differentiation and/or the production of neurites. 

    This ability to induce new neurons and/or the generation of projections by the surviving auditory neurons may itself facilitate the development of a novel therapy for deafness, or could be combined with current cochlear implants to improve their efficiency thereby increasing their usefulness. 

    For more information please download a summary of the technology from the link below

    27032AuditoryNeuronalDifferentiation.pdf

  • 27036 Colorimetric Sensors for DNA

    A researcher at the University of Sheffield has developed a novel colorimetric sensor with properties which include detecting the presence of DNA.   

    View more

    This chemical compound can interact with DNA in a specific manner and undergoes a visible colour change; this specificity may be related to the sequence or,

    more likely, the structure of the target DNA. The compound is a dinuclear Ruthenium-based coordination complex which can bind to DNA and undergoes a

    colour change from purple to green or blue depending upon the nature of the DNA.


    Some preliminary work suggests that the prototype molecule is not markedly cytotoxic and so could be used for research with live, rather than fixed, cells.

    A striking feature of the molecule is its apparent ability to specifically bind certain DNA structures, offering the possibility of the direct detection of these

    structures in living cells and the use of this compound as a tool for studying cell biology.  The image below shows the colour change of a solution of the

    compound on addition of calf thymus DNA. 

     

    For further information please download the summary information sheet below:

    PDF Link

  • 28061 Recombinant protein expression enhancer

    The University of Sheffield has identified that knocking down the level of expression of a specific endogenous protein, ubiquitous in mammalian cells, results in a significant increase in recombinant protein production. This observation provides a novel route to increase recombinant protein production by mammalian cells either in rapid, transient format or potentially for continuous production from stably engineered cells.

    View more

    Significant challenges remain in the production of proteins from mammalian cell expression systems and the ability to increase levels of recombinant protein production by mammalian cells would be an important advance for the biotechnology industry. The University of Sheffield has identified that knocking down the level of expression of a specific endogenous protein, ubiquitous in mammalian cells, results in a significant increase in recombinant protein production. This observation provides a novel route to increase recombinant protein production by mammalian cells either in rapid, transient format or potentially for continuous production from stably engineered cells.

    Knock-down of this single host cell protein results in a 4-5 fold increase in recombinant protein production during transient transfection of mammalian cells and the increase in expresion is observed for both secreted and non-secreted proteins.  It has been shown that the effect is independent of transfection reagent and target protein.

     

    Further information is available by downloading the PDF link below.

    Outlicensingopportunity28061recombinantproteinexpressionenhancer.pdf

  • 28013 - Transfer of cells using smart polymers

    This technology allows the development of a trypsin-free passaging system that could allow passage of stem cells without inducing differentiation, produces passaged cells with less damage than those treated by the traditional method and is useful in tissue engineering and is useful in tissue engineering, as it facilitates removal of cells without destroying the structure of the extracellular matrix.

    View more

    Researchers at the University of Sheffield have developed a hyperbranched thermoresponsive polymer which is soluble in aqueous media below a critical emperature, known as the lower critical solution temperature (LCST). When the temperature of the media is raised above the LCST, the polymer forms primary particles which aggregate and, unlike other thermoresponsive polymers which form a solid mass, our polymer forms a colloidal dispersion of sub-micron particles. This property means that the cells can be contacted with the polymer particles at temperatures above the LCST, causing cells to adhere to the polymer. In order to release cells from the polymer, the temperature of the solution is simply decreased below the LCST. 

    This technology is the subject a patent application that discloses this polymer and its uses in an array of possible applications.  For further information please download the summary document below: 

     

    Outlicensingopportunity28013Transferofcellsusingsmartpolymers.pdf

  • 27090 Low toxicity cellular stain

    A research group at the University of Sheffield has developed a series of novel chemical compounds suitable for live cellular staining applications with a unique combination of properties.

    View more

    Researchers require a detailed understanding of the processes and control points involved in specific diseases from inherited disorders to cancer and infections. Although much work has been done using cell-free systems where individual enzymes are analysed in vitro, there are always caveats about the relevance of such data to whole cells or organisms.  Until recently cell biologists were restricted to studying static, fixed tissue sections, raising concerns around artefacts introduced by sample preparation.  New instruments allow cell biologists to study living cells and tissues, providing dynamic, real-time data.  This instrumentation requires new reagents, such as cell stains, matched to its capabilities.

    Currently available staining systems are far from ideal for the following reasons:

    • Most have low water solubilities.
    • Their cellular uptake can be low so that staining can only be accomplished in fixed cells.
    • Most stains tend to be toxic, thus stained cells are only viable for 30 - 60 minutes.
    • They often have poor signal/noise ratios.

     A research group at the University of Sheffield has developed a series of novel chemical compounds suitable for use as reagents for this new cell biology.  The compounds appear to be very suitable for live cellular staining applications and have a unique combination of properties, including:  

    • Very low toxicity, which allows for long-term culture studies on labelled cells
    • High solubility in water, avoiding the need for incompatible organic solvents that might affect cells
    • Unique optical properties that provide a high signal-to-noise ratio
    • Straight-forward to synthesise in a few chemical steps using readily-available precursors making them suitable for scale-up to commercial manufacture
    • Fluorescent light output is highly dependent on its environment - it produces different colours when bound to different structures within a cell.

     For further information please download the summary document below:  

    27090LowToxicityCellularstain.pdf

  • 29038 Ultra-Broadband Superluminescent Diodes

    The first broadband high-power quantum dot superluminsecent diodes (QD-SLDs) to have been intermixed with a significant blue-shift in their operating wavelength have been demonstrated by Researchers at the University of Sheffield. This process could open the door to high bandwidth active devices comprising regions of different wavelengths that meet the demands of, for example, optical imaging of the eye and other skin tissue.

    View more

    Key features and benefits of this proprietary technology are:

    • Post- epitaxial growth intermixing for realising greater than 100 nm bandwidth sources
    • Modulation p-doping in the SLD for optimizing optical quality
    • Central emission wavelength of the intermixed sample blue shifted by ca. 100 nm which can lead to breakthrough and innovative selective area intermixed QD-SLD devices for high resolution imaging

    Intellectual Property

    This technology is protected by Patent Application filed in December 2009.

     

    The Opportunity

    The unique property of QD-SLDs, where high power output and broadband emission are simultaneously realised, make them ideal optical sources for many applications:

    • Optical Coherence Tomography (OCT) biomedical imaging applications - imaging the eye and other skin tissue
    • Fibre optic gyroscopes
    • Optical telecoms – wavelength division multiplexing

    The Researchers at Sheffield’s Centre for III-V materials have established demonstration facilities and considerable experience in OCT imaging systems. We are seeking commercial licensing and collaborative development opportunities for OCT and other cutting-edge applications.

    For more information, please click on the link to download a 1-page summary of this technology

    290381pagesummary.pdf

  • 27017 Nano-Goniometer for Electron Microscopy

    A research group at Sheffield University has designed a new multi-functional nanomanipulation device for specimens in the field of electron microscopic imaging. The device allows to perform manipulation and imaging processes in parallel and features translational and rotational degrees-of-freedom. In spite of its complex drive mechanism based on piezo-electric nanoactuation, the drive fits into a standard electron microscope goniometer. It complements the degrees-of-freedom built into a microscope by this “goniometer in goniometer” approach.

    View more

    Prospective fields of use will include:
    •Nanoscale resolution electron tomography with unlimited tilt range.

    •Contacting, welding and mechanical testing with user-defined crystallographic orientation relationships

    •Nanofabrication by beam-induced specimen modification (deposition/ablation)

     

    Intellectual Property

    A patent application on the device has been filed covering its use in numerous applications.

    Markets

    Sectors for application of such a goniometer comprise: composite materials research, physics and chemistry of atomic contact zones, semiconductor device technology, biomaterials, Catalysis and nanoparticle research

    Click on the link below for a one-page information sheet

    27017 Nano-goniometer.pdf

  • 24035 Block co-polymer

    A research group at the University of Sheffield have developed an opalescent (photonic) ink without the use of dyes. The material is suited to applications in printing, particularly in security.

    View more

    Researchers at the University of Sheffield have developed a film of a block copolymer dissolved in an acrylate blend. The block copolymer phase-separates in this blend to create a lamella phase. This lamella phase creates the optical colour shift effect. When the acrylates are exposed to UV irradiation they crosslink to form a hard chemically robust film. UV acrylates are commonly used in the print industry.

    The domain size is large enough to reflect light, without the use of dyes.

    The result is an opalescent film, the colour of which changes depending on the viewing angle. 

    For more information please download the non-confidential summary pdf from the link below:

    24035 one page summary.pdf

  • 24049 Neuro Fuzzy Network Modeling  

    The University of Sheffield has developed an advanced software package for Neuro-Fuzzy Network Modelling. This technique has been proven in a number of engineering applications such as data mining, pattern recognition, and process control/simulation

    View more

    The University of Sheffield has developed an advanced software package for Neuro-Fuzzy Network Modelling. This technique has been proven in a number of engineering applications such as data mining, pattern recognition, and process control/simulation

    The key features of interest in this proprietary software are:

    • Data mining and data visualisation in 2D and 3D
    • Input Selection for determining important input variables using statistical indices
    • Data Granulation for extracting knowledge out of a database
    • Model creation and optimisation for developing the modelling structure

    Intellectual Property

    Intellectual property in this software has been protected under the patent application WO 2006/103451

    The Opportunity

    The software has already been successfully utilised by companies with a need for a systematic method of generating neuro-fuzzy network models for non-linear high dimensional systems.  Applications have included :

    • The properties of heat treated steel based on the chemical composition
    • The outcome of heat treatment regimes on steels 
    • Patient ventilation performance in an Intensive Care Unit

    For more information, please download a 1-page summary from the link below:

    240491pagesummary.pdf

Focus on

28061 Recombinant protein expression enhancer

The University of Sheffield has identified that knocking down the level of expression of a specific endogenous protein, ubiquitous in mammalian cells, results in a significant increase in recombinant protein production. This observation provides a novel route to increase recombinant protein production by mammalian cells either in rapid, transient format or potentially for continuous production from stably engineered cells.

View similar Opportunities »

Key